NCT04532645 2025-09-23
OVAL-1
AstraZeneca
Completed
Clinical Trials
23 trialsNCT00753545 2025-02-03
Assessment of Efficacy of AZD2281 in Platinum Sensitive Relapsed Serous Ovarian Cancer
AstraZeneca
Phase 2 Completed
NCT03314740 2025-01-10
BAROCCO
Mario Negri Institute for Pharmacological Research
Phase 2 Completed
NCT02953457 2024-11-19
Olaparib, Durvalumab, and Tremelimumab in Treating Patients With Recurrent or Refractory Ovarian, Fallopian Tube or Primary Peritoneal Cancer With BRCA1 or BRCA2 Mutation
Roswell Park Cancer Institute
Phase 2 Completed
NCT03378297 2024-10-30
IMPACT
Haukeland University Hospital
Phase EARLY_PHASE1 Completed
NCT03402841 2024-08-21
OPINION
AstraZeneca
Phase 3 Completed
NCT00516373 2024-02-22
A Study to Assess the Safety and Pharmacokinetics of an Inhibitor of Poly ADP-Ribose Polymerase-1 (PARP)
AstraZeneca
Phase 1 Completed
NCT03117933 2024-01-23
OCTOVA
University of Oxford
Phase 2 Completed
NCT04669002 2023-08-02
EP0057 in Combination With Olaparib in Advanced Ovarian Cancer
Ellipses Pharma
Phase 2 Completed
NCT00679783 2023-07-12
Phase II Study of AZD2281 in Patients With Known BRCA Mutation Status or Recurrent High Grade Ovarian Cancer or Patients With Known BRCA Mutation Status/ Triple Neg Breast Cancer
AstraZeneca
Phase 2 Completed
NCT04417192 2023-07-06
OLAPem
National Cancer Center Hospital East
Phase 2 Completed
NCT03470805 2022-09-23
Olaparib After Response to Trabectedin-pegylated Liposomal Doxorubicin in Recurrent Ovarian Carcinoma
Grupo Español de Investigación en Cáncer de Ovario
Phase 2 Completed
NCT02477644 2022-08-02
PAOLA-1
Arcagy Research
Phase 3 Completed
NCT02282020 2022-07-26
SOLO3
AstraZeneca
Phase 3 Completed
NCT02681237 2022-05-09
A Study of Cediranib and Olaparib at Disease Worsening in Ovarian Cancer
University Health Network, Toronto
Phase NA Completed
NCT02889900 2022-03-08
CONCERTO
AstraZeneca
Phase 2 Completed
NCT02855697 2022-02-22
MOLTO
The Christie NHS Foundation Trust
Phase EARLY_PHASE1 Completed
NCT03205176 2021-05-06
AZD5153 in Patients With Relapsed or Refractory Solid Tumors, Including Lymphomas
AstraZeneca
Phase 1 Completed
NCT01623349 2021-02-10
Phase I Study of the Oral PI3kinase Inhibitor BKM120 or BYL719 and the Oral PARP Inhibitor Olaparib in Patients With Recurrent Triple Negative Breast Cancer or High Grade Serous Ovarian Cancer
Dana-Farber Cancer Institute
Phase 1 Completed
NCT02121990 2020-08-21
Dose-Escalation Study of Intraperitoneal (IP) Cisplatin, IV/IP Paclitaxel, IV Bevacizumab, and Oral Olaparib for Newly Diagnosed Ovarian, Primary Peritoneal, and Fallopian Tube Cancer
Memorial Sloan Kettering Cancer Center
Phase 1 Completed
NCT01237067 2019-12-17
Olaparib in Combination With Carboplatin for Refractory or Recurrent Women s Cancers
National Institutes of Health Clinical Center (CC)
Phase 1 Completed
NCT00628251 2019-12-05
ICEBERG 3
AstraZeneca
Phase 2 Completed
NCT02418624 2019-01-16
REVIVAL
The Netherlands Cancer Institute
Phase 1 Completed